Edi­to­rial: “Together we are strong”

Dear readers, dear busi­ness asso­ciates, Corona has plunged the world into a deep crisis. But a large number of com­pa­nies quickly took the ini­tia­tive: Research on med­i­cines and vac­cines is being con­ducted all over the world. Even beyond Covid-19, time does not stand still. Inter­na­tion­ally, experts con­tinue to work intensely on inno­v­a­tive drugs and technologies […]

Dear readers,
dear busi­ness associates,

Corona has plunged the world into a deep crisis. But a large number of com­pa­nies quickly took the ini­tia­tive: Research on med­i­cines and vac­cines is being con­ducted all over the world. Even beyond Covid-19, time does not stand still. Inter­na­tion­ally, experts con­tinue to work intensely on inno­v­a­tive drugs and tech­nolo­gies that keep people healthy, cure them – or make their lives easier.

Together with our cus­tomers, we pursue future-ori­ented trends and sup­port the devel­op­ment of new dosage forms with our tech­nolo­gies. An example is the Accor­dion Pill® by Intec Pharma: A folded, multi-layer polymer film in a hard cap­sule releases the active ingre­dient in a con­trolled manner. For the bio­phar­ma­ceu­tical com­pany Zosano Pharma, we designed a fully auto­mated line for the high-pre­ci­sion coating of tita­nium micronee­dles. They form the cen­ter­piece of a patch that is sup­posed to pro­vide faster relief for migraine patients in the future. In addi­tion, we have taken a major step in the field of future-ori­ented vac­ci­na­tion tech­nology using micronee­dles. Our long-standing devel­op­ment work with Vaxxas is moving on to the next stage: The man­u­fac­ture of a pilot line for the new microneedle device with the sup­port of orga­ni­za­tions such as the Gates Foun­da­tion, PATH and the WHO.

Per­son­al­ized med­i­cine is a topic that could rev­o­lu­tionize the phar­ma­ceu­tical industry. In this field, too, we are expanding our net­work of spe­cial­ized partner com­pa­nies and are advancing the tech­no­log­ical devel­op­ment of these trends. For instance, we recently entered into a strategic part­ner­ship with DiH­eSys Dig­ital Health Sys­tems – together we develop solu­tions for 2D and 3D printing to enable per­son­al­ized pro­duc­tion of medicines.

“Together we are strong” has been our motto not just since Corona. We have been living it for decades with reli­able, trusting part­ner­ships. As early as 1988, Harro Höfliger received the first order for the aseptic assembly of syringes for a world-­leading oncology drug from AstraZeneca. The coop­er­a­tion has been con­tin­uing until today.

The future holds many chal­lenges in store for us. Let us over­come them together.

Stay healthy,

Your
Thomas Weller, 
CEO at Harro Höfliger

Down­load this article as PDF file

Photo: Janine Kyofsky